286 related articles for article (PubMed ID: 38499572)
1. Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics.
Kirouac DC; Zmurchok C; Morris D
NPJ Syst Biol Appl; 2024 Mar; 10(1):31. PubMed ID: 38499572
[TBL] [Abstract][Full Text] [Related]
2. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
3. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development.
Kast J; Nozohouri S; Zhou D; Yago MR; Chen PW; Ahamadi M; Dutta S; Upreti VV
Clin Transl Sci; 2022 Sep; 15(9):2057-2074. PubMed ID: 35677992
[TBL] [Abstract][Full Text] [Related]
5. Deconvolution of clinical variance in CAR-T cell pharmacology and response.
Kirouac DC; Zmurchok C; Deyati A; Sicherman J; Bond C; Zandstra PW
Nat Biotechnol; 2023 Nov; 41(11):1606-1617. PubMed ID: 36849828
[TBL] [Abstract][Full Text] [Related]
6. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
7. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
8. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology.
Huang W; Li J; Liao MZ; Liu SN; Yu J; Jing J; Kotani N; Kamen L; Guelman S; Miles DR
Clin Pharmacol Ther; 2022 Nov; 112(5):968-981. PubMed ID: 34888856
[TBL] [Abstract][Full Text] [Related]
10. Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells.
Holzinger A; Abken H
Pharmacology; 2022; 107(9-10):446-463. PubMed ID: 35696994
[TBL] [Abstract][Full Text] [Related]
11. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.
Qi T; McGrath K; Ranganathan R; Dotti G; Cao Y
Adv Drug Deliv Rev; 2022 Sep; 188():114421. PubMed ID: 35809868
[TBL] [Abstract][Full Text] [Related]
12. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
13. Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies.
Zhu I; Piraner DI; Roybal KT
Cancer Immunol Res; 2023 Aug; 11(8):1030-1043. PubMed ID: 37429007
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
15. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches.
Chaudhury A; Zhu X; Chu L; Goliaei A; June CH; Kearns JD; Stein AM
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S147-S159. PubMed ID: 33205434
[TBL] [Abstract][Full Text] [Related]
17. Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
Bunse M; Höpken UE
Methods Mol Biol; 2022; 2521():67-83. PubMed ID: 35732993
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Yoon DH; Osborn MJ; Tolar J; Kim CJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
[TBL] [Abstract][Full Text] [Related]
19. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]